Cognitive Effects and Potential Mechanisms of TBS in Subjects With MCI
Biomarker-based Prediction of Cognitive Effects and Potential Mechanisms of Theta-burst Stimulation (TBS) in Subjects With Mild Cognitive Impairment (MCI)
1 other identifier
interventional
80
1 country
1
Brief Summary
This study aims to examine the effects and potential mechanisms of theta-burst stimulation (TBS) on cognitive function in individuals with mild cognitive impairment (MCI).
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Sep 2022
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 27, 2022
CompletedFirst Posted
Study publicly available on registry
July 7, 2022
CompletedStudy Start
First participant enrolled
September 13, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 30, 2027
March 23, 2026
March 1, 2026
4.8 years
June 27, 2022
March 19, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Mini-Mental State Examination ( MMSE )
Change from baseline Mini-Mental State Examination total scores immediately after TBS intervention
Baseline and immediately after 2 weeks of TBS and 8-week follow-up after TBS
Montreal Cognitive Assessment
Change from baseline Montreal Cognitive Assessment total scores immediately after TBS intervention
Baseline and immediately after 2 weeks of TBS and 8-week follow-up after TBS
Secondary Outcomes (1)
The standard uptake values changes of FDG-PET
Before and immediately after TBS intervention
Study Arms (2)
Amyloid-positive MCI
ACTIVE COMPARATORThe subjects will receive active stimulation of standard intermittent TBS (iTBS) protocol.
Amyloid-negative MCI
ACTIVE COMPARATORThe subjects will receive active stimulation of standard intermittent TBS (iTBS) protocol.
Interventions
The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50-Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min.
The investigators will perform standard intermittent TBS (iTBS) parameters to left DLPFC of every patient in the study. The frequency parameters of TBS are 3-pulse 50-Hz bursts, every 200 ms at 5 Hz, and the intensity is 90% of active motor threshold. A single session of iTBS contains 2 s of TBS repeated every 10 s for 20 times. In this study, The investigators will give two sessions of iTBS separated by 15 min.
Eligibility Criteria
You may qualify if:
- Subjects aged 50-90 year
- Subjects meet Petersen's criteria for mild cognitive impairment (Petersen, Smith et al. 1999)
- The CDR of MCI patients can be 0-0.5
- Amyloid PET should ever be performed
You may not qualify if:
- Any subject has a definite diagnosis of epilepsy or history of seizure attack.
- Current or past history of clinically significant neurological insults affecting brain structure or function like completed stroke, head injury or brain tumor.
- Any subject has clinically significant or unstable medical diseases including metabolic, renal,liver, lung or cardiovascular disorders including metabolic, renal, liver, lung or cardiovascular disorders.
- Any subject has current alcohol or other substances abuse and/ or dependence within the recent one year, or prolonged history of major psychiatric disorder like schizophrenia,bipolar disorder, and previously prolonged substances abuse.
- Any females who is pregnant or lactating.
- Withdrawal criteria
- Complications onset after intervention that affect efficacy and safety judgments.
- New onset or progression of disease that may affect outcomes.
- Use of other therapies or drugs during the intervention period to change cognitive functions.
- Any subjects who are recognized as high risk of adverse effects by principle investigator.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Chang Gung Memorial Hospital
Taoyuan District, Taiwan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
KUAN YI WU
Chang Gung Memorial Hospital
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 27, 2022
First Posted
July 7, 2022
Study Start
September 13, 2022
Primary Completion (Estimated)
June 30, 2027
Study Completion (Estimated)
June 30, 2027
Last Updated
March 23, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will not share